Optimization of the efficacy and safety of antidepressant therapy in patients of a geriatric psychiatric unit

Гаврилова, С. И.; Kalyn, Ya. B.; Сафарова, Т. П.; Yakovleva, O. B.; Sheshenin, V.; Корнилов, В. В.; Шипилова, Е. С.

doi:10.17116/jnevro20151156124-32

Cited by 9 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many clinical studies ( 44 , 45 ) have confirmed that, compared with established antidepressants, ALC can significantly reduce depressive symptoms and have similar effects. However, no studies have reported the changes of LC and ALC levels in patients after antidepressant treatment.…”

Section: Discussionmentioning

confidence: 96%

L-Carnitine and Acetyl-L-Carnitine: Potential Novel Biomarkers for Major Depressive Disorder

et al. 2021

View full text Add to dashboard Cite

The lack of biomarkers greatly limits the diagnosis and treatment of major depressive disorder (MDD). Endogenous L-carnitine (LC) and its derivative acetyl-L-carnitine (ALC) play antidepressant roles by improving brain energy metabolism, regulating neurotransmitters and neural plasticity. The levels of ALC in people and rodents with depression are significantly reduced. It is necessary to determine whether serum LC and ALC might be used as novel biomarkers for the diagnosis of MDD. Here, ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was used to determine the concentration of LC and ALC in the serum of healthy controls and patients with MDD; among the latter, in patients who were responsive (effective group) and non-responsive (ineffective group) after 2 weeks of treatment. The diagnostic value of serum LC and ALC for MDD was assessed. Compared with healthy controls, the serum LC and ALC concentrations in patients with MDD were significantly decreased (P < 0.001). Pearson correlation analysis shows that the HDRS-24 score was negatively associated with serum ALC (r = −0.325, P = 0.007). Receiver operating characteristic (ROC) analysis revealed an area under the curve (AUC) of 0.801 with 83.1% sensitivity and 66.3% specificity for LC, and an AUC of 0.898 with 88.8% sensitivity and 76.4% specificity for ALC, differentiating patients with MDD from healthy controls. Furthermore, the concentration of LC and ALC in patients with depression was significantly increased in the effective treatment group, and no significant change was observed in the ineffective treatment group. These results suggest that serum LC and ALC may be novel biomarkers for the diagnosis of MDD.

show abstract

Section: Discussionmentioning

confidence: 96%

L-Carnitine and Acetyl-L-Carnitine: Potential Novel Biomarkers for Major Depressive Disorder

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Many clinical studies [38][39] have con rmed that ALC can signi cantly reduce the symptoms of depression compared with the established antidepressants and has similar effectiveness. However, no studies have reported the changes of LC and ALC levels in patients after treatment with antidepressant drugs.…”

Section: Discussionmentioning

confidence: 99%

L-carnitine and acetyl-L-carnitine: potential novel biomarkers for major depressive disorder

Nie¹,

Liang²,

Feng³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background The lack of biomarkers to identify the target population has greatly limited the precise medical prospects for major depressive disorder (MDD). The endogenous L-carnitine (LC) and its derivative acetyl-L-carnitine (ALC) play different roles in depression, from metabolism and neurochemistry to epigenetic roles. The levels of ALC in people and rodents with depression are significantly reduced. It is necessary to determine whether serum LC and ALC might be used as novel noninvasive biomarkers for the diagnosis of MDD. Methods Ultra-performance liquid chromatography–electrospray–tandem mass spectrometry (UPLC–ESI-MS/MS) was used to determine the concentration of LC and ALC in the serum of healthy controls and patients with MDD; among the latter, in patients who were responsive (effective group) and those who were nonresponsive (ineffective group) after 2–4 weeks of treatment. The diagnostic value of serum LC and ALC for MDD was assessed. Results Serum LC and ALC concentrations were significantly lower in patients with MDD than in healthy controls. The Pearson correlation analysis showed that the HDRS-24 score was positively associated with serum ALC. The ROC analysis revealed an AUC of 0.6943 with 61.0% sensitivity and 74.0% specificity for LC and an AUC of 0.8496 with 67.0% sensitivity and 93.0% specificity for ALC, differentiating patients with MDD from healthy controls. Furthermore, the concentration of LC and ALC in patients with depression was significantly increased in the effective-treatment group and no significant change was observed in the ineffective-treatment group. Conclusion These results suggest that serum LC and ALC might be potential novel biomarkers for the diagnosis of MDD.

show abstract

Acetyl-l-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis

Veronese¹,

Stubbs²,

Solmi

et al. 2018

Psychosom Med

View full text Add to dashboard Cite

show abstract

Optimization of the efficacy and safety of antidepressant therapy in patients of a geriatric psychiatric unit

Abstract: Antidepressant/carnicetine combination therapy may be recommended for treatment of depression in elderly patients.

Cited by 9 publications

References 14 publications

L-Carnitine and Acetyl-L-Carnitine: Potential Novel Biomarkers for Major Depressive Disorder

L-Carnitine and Acetyl-L-Carnitine: Potential Novel Biomarkers for Major Depressive Disorder

L-carnitine and acetyl-L-carnitine: potential novel biomarkers for major depressive disorder

Acetyl-l-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About